Biofrontera Inc.

NasdaqCM BFRI

Biofrontera Inc. Goodwill for the quarter ending September 30, 2024: USD 0.00

Biofrontera Inc. Goodwill is USD 0.00 for the quarter ending September 30, 2024, a 0.00% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

Biofrontera Inc. Goodwill for the quarter ending September 30, 2023 was USD 0.00, a 0.00% change year over year.
Biofrontera Inc. Goodwill for the quarter ending September 30, 2022 was USD 0.00.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

NasdaqCM: BFRI

Biofrontera Inc.

CEO	Dr. Hermann Luebbert Ph.D.
IPO Date	Oct. 29, 2021
Location	United States
Headquarters	120 Presidential Way
Employees	83
Sector	Health Care
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies

Description

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Key trends

Past 5 years